U.S. markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9200-0.1100 (-5.42%)
At close: 04:00PM EDT
1.9900 +0.07 (+3.65%)
After hours: 04:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.0300
Bid1.9100 x 4000
Ask1.9900 x 4000
Day's Range1.9100 - 2.0200
52 Week Range1.8600 - 3.1500
Avg. Volume583,595
Market Cap321.709M
Beta (5Y Monthly)2.13
PE Ratio (TTM)N/A
EPS (TTM)-0.4600
Earnings DateNov 07, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ABUS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arbutus Biopharma Corporation
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Zacks

    Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up

    Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.

  • GlobeNewswire

    Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

    Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 WARMINSTER, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that tar

  • GlobeNewswire

    Arbutus to Participate in Two Upcoming Investor Conferences

    WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference: Formal Presentation on September 12, 202